

Evolving Landscape of Real-World Evidence Research Practice and Policy

Heather M. Colvin, MPP
Senior Director, International Harmonization
Global Regulatory Policy
Johnson & Johnson Medtech

15 September 2025





Presentation Topics

Current Global Regulatory Landscape for Real-World Evidence
Policies

Rapid Evolution of Real-World Evidence Research

- Real World Data

- Analytical Methods

- Research Practices

- Interpretation and Analysis

Current Global Regulatory Landscape for Real-World Evidence Policies

Insights from EU IHI Public Private Partnership



Integration of Heterogeneous Data and Evidence towards Regulatory and HTA Acceptance

Funding Acknowledgement

This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112135. The JU receives support from the European Union's Horizon Europe research and innovation programme and life science industries represented by COCIR, EFPIA / Vaccines Europe, EuropaBio and MedTech Europe.

In addition, there are financial and/or in-kind contributions from our Swiss and UK partners. The UK participant is supported by UKRI grant No 10079453 (National Institute for Health and Care Excellence).

IDERHA is funded by the European Union, the private members, and those contributing partners of the IHI JU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.



Co-funded by
the European Union

IDERHA Consortium Partners

industry

academia

data / clinical

public

SME

Johnson&Johnson
MedTech

 **Fraunhofer**

VTT

 **LÆGEMIDDELSTYRELSEN**
DANISH MEDICINES AGENCY

 **hygia so**

Johnson&Johnson
Innovative Medicine

FH University of Applied Sciences
TECHNIKUM
WIEN

 **ASKLEPIOS**
A SERVICIO ANDALUZ DE SALUD
Consejería de Salud y Consumo

NICE
National Institute
for Health and
Care Excellence

ITTM
Information Technology
for Translational Medicine

PHILIPS

iHD The European Institute
for Innovation through
Health Data

MSB Medical School Berlin
Hochschule für
Gesundheit und Medizin

 **Lung Cancer Europe**



 **labcorp**

 **MEDICAL UNIVERSITY
OF VIENNA**

A
Junta de Andalucía
Consejería de Salud y Consumo
Fundación Pública Andaluza
para la Gestión de la Investigación
en Salud de Sevilla (FISEVI)

EPF European
Patients
Forum

sanofi

 |  **LCSB**

 **SERVIZO
GALEGO
DE SAÚDE**

 **ERS** EUROPEAN
RESPIRATORY
SOCIETY
every breath counts

 **Roche**

 **TUM**
Klinikum rechts der Isar
Technische Universität München

 **IIS La Fe**
Health Research Institute


lygature
pioneering medicine.
together.

 **Takeda**

 **LUDWIG
BOLTZMANN
INSTITUTE**
Digital Health and Prevention

 **FISEVI**
Fundación Pública Andaluza para la
Gestión de la Investigación en
Salud de Sevilla

**JE
FACT
UM**



Advancing Harmonized RWE Policies

Project Goal

Provide well-researched and consensus-driven recommendations to **Inform** and **Accelerate** harmonized Real-World Evidence policy development



Landscape of RWD/RWE Specific Policies

- Global scope
- Policies for:
 - Regulatory & HTA organizations
 - Medicines and Medical Devices
- 2017 to January 2024
- English text only or translations

Overview of analysed documents

Definitions of key terms (e.g., RWD/RWE)

Uses of RWD and RWE

Guidance on study design and conduct

Data collection, curation, & characterization

Data quality assessment

Ethics, governance, trust, and transparency

Intersection of RWD/RWE and AI

Global Landscape Review

Regulatory

US FDA
Health Canada

HTA

CADTH (CAN)
ICER (US)

3rd party

NESTcc (US)

Regulatory

ANVISA (Brazil)

Regulatory

EMA (EU)
MHRA (UK)
Swissmedic (CH)

HTA

HAS (FR)
IQWiG (DE)
EUNetHTA (EU)

3rd party

NICE (UK)
IMI (EU)
ZIN(NL)

Regulatory

NMPA (CN)
PSEHB &
PMDA (JP)
NIFDSE &
MFDS (KR)

HTA

REALISE
working
group
(mixed)

Regulatory

TGA (AUS)

International 3rd party

- ICH
- IMDRF
- HTAi
- ISPOR
- ISPE
- OHE

Findings of RWE Policies Landscape Review

Project Goal

Provide well-researched and consensus-driven recommendations to **Inform** and **Accelerate** harmonized Real-World Evidence policy development



Landscape of RWD/RWE Specific Policies


- Global scope
- Policies for:
 - Regulatory & HTA organizations
 - Medicines and Medical Devices
- 2017 to January 2024
- English text only or translations




Evolving Organizational Perspectives

Policy & programmatic changes are needed to ensure high-quality and transparent research to build trust.


Emerging Best Practices



Policy Gaps




Medical Device RWE Activities & Guidances




Rapid Evolution of Real-World Evidence Research






Components of Real-World Evidence Policy Guidance




Assessing the RWE Fit for Purpose to the Study Question

Inter-relationship between the Study Question, Data Sources and Research Methods



Deeper Understanding of Real-World Data Sources



Advances in Evaluating Fit-for-Use of RWD

Fitness for Use*

Data Reliability*

Assessing and Characterizing the Real-World Data
Source

Accuracy

Completeness

Traceability

Data Relevance*

Assessing the Individual Real World Data Elements for the Study
Question

Availability

Linkages

Timeliness


Generalizability

*Sources:

- DRAFT Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices guidance. FDA 2023. Available at: <https://www.fda.gov/media/99447/download>; <https://www.fda.gov/media/174819/download>
- Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products; Draft Guidance for Industry. FDA 2021.

Assessing the RWE Fit for Purpose to the Study Question

Inter-relationship between the Study Question, Data Sources and Research Methods



Advancements in Methods



**Data Linkage &
Standardization**



**Bias &
Confounding**

Research Standardization



**Research
Transparency**



**Procedural
Guidance**

Interpretation of Study Results

Study Strengths and Limitations


- Assess study results in the context of data, study design, and data analysis
 - Sample size and statistical power
 - Potential residual confounding and biases
 - Generalizability

Consistency of Study Results



Assessing the RWE Fit for Purpose to the Study Question

Inter-relationship between the Study Question, Data Sources and Research Methods



Transparency in Research Practices
Consistent and shared expectations



Growing Need for Evidence

Evolution of Medical Products



Expanding Sources of Clinical Data & Evidence



Emerging Needs of Decision Makers

